Pritelivir mesylate

• CAS: 1428333-96-3
• Catalog Number: ACM1428333963
• Category: Inhibitors
• Molecular Weight: 498.59
• Molecular Formula: C19H22N4O6S3
• Description: Pritelivir, also known as AIC-316 and BAY 57-1293, is a potent helicase primase inhibitor. BAY 57-1293 inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. The compound shows profound antiviral activity in murine and rat lethal challenge models of disseminated herpes, in a murine zosteriform spread model of cutaneous disease, and in a murine ocular herpes model. It is active in parenteral, oral, and topical formulations.
• Synonyms: Pritelivir mesylate, BAY57-1293; BAY 57-1293; BAY-57-1293; BAY571293; BAY 571293; BAY-571293; AIC-316; AIC 316; AIC316
• IUPAC Name: N-methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide mesylate
• Canonical SMILES: O=C(N(C)C1=NC(C)=C(S(=O)(N)=O)S1)CC2=CC=C(C3=NC=CC=C3)C=C2.OS(=O)(C)=O
• InChI: InChI=1S/C18H18N4O3S2.CH4O3S/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15;1-5(2,3)4/h3-10H,11H2,1-2H3,(H2,19,24,25);1H3,(H,2,3,4)
• InChI Key: PPAJHCGEURRDOG-UHFFFAOYSA-N
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Shelf Life: >2 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Alternative CAS: 1428333-96-3 (mseylate); 348086-71-5 (free base); 910864-57-2 (HCl); 910864-61-8 (besylate); 2088209-68-9 (sulfate)
• Biological Target: Pritelivir mesylate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2.
• Drug Formulation: This drug may be formulated in DMSO
• Elemental Analysis: C, 45.77; H, 4.45; N, 11.24; O, 19.25; S, 19.29
• Exact Mass: 498.0701
• HS Tariff Code: 2934.99.9001
• In Vitro Activity: To mimic patient conditions during primary infection contrasting the prophylactic approach described, skin was first infected with; HSV-1 for 4 days. Infected skin was further cultured with virus-free cell culture medium for 3 days in the presence or absence of; pritelivir to measure its therapeutic potential. RT-PCR showed that pritelivir partly inhibited further replication by 62.3% compared; with non-drug-treated, HSV-1-infected control (100%) (Figure 4e).; Reference: J Invest Dermatol. 2019 Mar;139(3):673-682. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100788/
• In Vivo Activity: Mice lethally infected with HSV type 1 or 2 were treated 72 hours after infection for 7 days with pritelivir administered orally twice; daily. Dosages of pritelivir from 0.3 to 30 mg/kg reduced mortality (P<0.001) against HSV-1, E-377. With an acyclovir resistant; HSV-1, 11360, pritelivir at 1 and 3 mg/kg increased survival (P<0.005). With HSV-2, MS infected mice, all dosages higher than the; 0.3 mg/kg dose of pritelivir were effective (P<0.005). These results suggest that pritelivir has potent and resistance-breaking antiviral; efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex; encephalitis.; Reference: Antiviral Res. 2018 Jan;149:1-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743594/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).